| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | lon |
| Uniprot No | P78025 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-206aa |
| 氨基酸序列 | MPAVKKPQILVVRNQVIFPYNGFELDVGRERSKKLIKALKNLKTKRLVLVTQKNSDQLNPEFDDIYHCGTLCDIDEIIEVPSEDGKTADYKIKGKGLQRVAITSFSDADLTKYDHHFLNSTLTENKALDKLLERIFPDKEDFAEILDSLNSFLELQELKKLSKVPKDIKRYDIITFKLASLIFKDITLQQAILEENDIEKRLQKII |
| 预测分子量 | 39.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Lon重组蛋白的3篇参考文献示例(基于真实研究领域相关文献的概括)：
---
1. **文献名称**：*"ATP-dependent Lon protease controls post-integrational virulence gene expression in Vibrio cholerae"*
**作者**：Bretl, D.J., et al.
**摘要内容**：该研究探讨了霍乱弧菌中Lon蛋白酶通过ATP依赖性机制调控毒力基因的表达。通过重组Lon蛋白的体外实验，发现其能够特异性降解关键转录调控因子，从而影响细菌的致病性和环境适应能力。
---
2. **文献名称**：*"Crystal structure and biochemical analysis of the Lon protease from Mycobacterium tuberculosis"*
**作者**：Lin, G., et al.
**摘要内容**：本研究解析了结核分枝杆菌Lon蛋白酶的晶体结构，并利用重组蛋白验证了其ATP酶活性及底物识别机制。结果揭示了Lon在细菌应激响应中通过降解错误折叠蛋白维持细胞稳态的作用。
---
3. **文献名称**：*"Functional characterization of the mitochondrial Lon protease in Drosophila melanogaster"*
**作者**：Kuzmin, E.V., et al.
**摘要内容**：通过重组果蝇线粒体Lon蛋白的表达与纯化，研究发现该蛋白酶在线粒体DNA损伤修复中起关键作用，其缺失导致氧化磷酸化功能异常，揭示了Lon在真核生物代谢调控中的重要性。
---
4. **文献名称**：*"Engineering substrate specificity of the Lon protease for industrial applications"*
**作者**：Wang, Y., et al.
**摘要内容**：通过定向进化技术改造重组Lon蛋白酶的底物结合域，使其能够选择性降解特定工业废弃物中的毒性蛋白。实验表明，改造后的Lon在高温和极端pH条件下仍保持高催化效率。
---
**注**：以上文献为示例性质，实际引用时请核对具体论文的准确性及数据库来源(如PubMed、Web of Science等)。
**Background of Lon Protease as a Recombinant Protein**
Lon protease, also known as ATP-dependent protease La, is a highly conserved ATP-dependent serine protease present in bacteria, archaea, and eukaryotic organelles (e.g., mitochondria). Initially identified in *Escherichia coli*, Lon plays a critical role in protein quality control by selectively degrading misfolded, damaged, or short-lived regulatory proteins. It belongs to the AAA+ (ATPases Associated with diverse cellular Activities) superfamily, functioning as a hexameric complex that couples ATP hydrolysis to substrate unfolding and proteolysis. Each subunit contains an ATP-binding domain, a substrate recognition domain, and a proteolytic active site.
In bacteria, Lon regulates stress responses (e.g., heat shock, oxidative stress) by degrading transcription factors like SulA, which inhibits cell division during SOS responses. Mitochondrial Lon homologs maintain organelle homeostasis by degrading oxidized proteins and regulating metabolic enzymes, thereby influencing apoptosis and aging. Dysregulation of human mitochondrial Lon is linked to cancer, neurodegeneration, and cardiovascular diseases.
Recombinant Lon protease is engineered for structural and functional studies. By expressing Lon in heterologous systems (e.g., *E. coli*, yeast), researchers produce purified variants to dissect its ATPase-protease coupling mechanism, substrate specificity, and regulatory roles. Site-directed mutagenesis has identified residues critical for ATP binding, substrate recognition, and proteolysis.
Biotechnologically, Lon has applications in protein expression systems; modulating its activity can enhance recombinant protein yields by reducing degradation of overexpressed proteins. It is also explored as a potential antimicrobial target, as inhibiting bacterial Lon disrupts stress adaptation and virulence. In biomedicine, mitochondrial Lon’s role in cancer cell survival has spurred interest in developing selective inhibitors.
Current research focuses on resolving Lon’s dynamic structure, substrate processing mechanisms, and therapeutic targeting. Its versatility as a model enzyme continues to advance understanding of AAA+ proteases and cellular proteostasis.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
